Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate, Feiba), By Type of Hemophilia, By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement, Immune Tolerance Induction) Outlook 2022
Format : 
Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : May, 2017| No. of Pages : 95
Please make your selection :
Electronic Access - Single User License
US$ 2500.00
CD-ROM Mail Delivery
US$ 2700.00
Hard Copy Mail Delivery
US$ 2700.00
Electronic Access - Multi-User License
US$ 3500.00
1. Analyst View
2. Research Methodology
3. Hemophilia: An Overview
4. Market Dynamics
4.1 Drivers
4.1.1 Development of Inhibitors in Hemophilia Patients
4.1.2 Rising Healthcare Expenditure
4.1.3 Increasing Awareness
4.1.4 Rising Life Expectancy
4.1.5 Grants and Tax Credits
4.1.6 Shorter Development Timeline and Orphan Drug Exclusivity (ODE)
4.2 Challenges
4.2.1 Manufacturing Difficulties
4.2.2 Low Switching Rate
4.3 Opportunities
4.3.1 Incessant Launch of New Generation of Recombinant Factor Products
4.3.2 Growing Geriatric Population
5. Global Hemophilia Therapeutics Market Outlook 2022
6. Major Products in Hemophilia Therapeutics Market
6.1 Advate
6.2 NovoSeven/NovoSeven RT
6.3 Kogenate/Kovaltry
6.4 Feiba
6.5 BeneFix
6.6 ReFacto AF/Xyntha
6.7 Eloctate/Elocta
6.8 Alprolix
6.9 Alphanate
6.10 Rixubis
6.11 NovoEight
6.12 Adynovate/Adynovi
7. Market Segmentation by Type of Hemophilia
7.1 Hemophilia A
7.2 Hemophilia B
7.3 Others
8. Market Segmentation by Type of Treatment
8.1 On-Demand
8.2 Prophylaxis
9. Market Segmentation by Type of Therapy
9.1 Replacement Therapy
9.2 Immune Tolerance Induction Therapy
10. Market Segmentation by Geography
10.1 North America
10.2 Europe
10.3 Asia-Pacific
11. Gene Therapy - Future of Hemophilia Treatment
12. Trends & Developments
13. Mergers & Acquisitions
14. Pipeline Analysis
15. Company Profiles
15.1 Novo Nordisk A/S
15.2 Pfizer Inc.
15.3 F. Hoffmann-La Roche Ltd.
15.4 Bayer AG
15.5 Shire plc
15.6 CSL Limited
15.7 Octapharma AG
15.8 Grifols International SA
15.9 Swedish Orphan Biovitrum AB
15.10 Alnylam Pharmaceuticals, Inc.
Not able to find data you are looking for? Ask our Research Analyst.
media citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2018, RNCOS, 2002-2018
About Us
Terms & Policy
Contact